Mark O'Herlihy explains how and why machine learning will be fundamental to the healthcare of tomorrow, admitting that there is still a great deal of work to be done to demystify the role of new technologies by identifying proven results and best practice.
“We are years ahead of any competitor that may appear in the future,” says Claudia Jimenez, General Manager of biotech company ALGENEX, which uses moths to develop vaccines.
Stephan Sturm, Global CEO of Fresenius Group, says that we are fast approaching a new world of care, with a much stronger focus on prevention and more personalised treatment pathways.
Micro-immunotherapy can be used as supportive therapy for diseases which are the consequence of an imbalance in the immune system and has far fewer side effects than other treatments, explains Ian Wilders, Labo’Life’s Group CEO.
Laurent Monnerat of Zoetis explains how digital disruption is having a considerable impact on how animal health is being practiced.
Michael Schmelmer, CFO at Boehringer Ingelheim outlines his firm’s efforts to excel in pharma’s digital future and the abundant opportunities that lie therein.
Mark Ware, Chief Medical Officer at Canopy Growth Corporation, shares his vision for the future of the medical cannabis sector and says there is massive patient demand; however, research and clinical trials have yet to catch up to position cannabis as a respected medical product.
By continuing to use the site, you agree to the use of cookies. more information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.